1. Home
  2. AMPH vs ANNX Comparison

AMPH vs ANNX Comparison

Compare AMPH & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$18.72

Market Cap

971.8M

Sector

Health Care

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.36

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPH
ANNX
Founded
1996
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.8M
812.7M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
AMPH
ANNX
Price
$18.72
$5.36
Analyst Decision
Buy
Strong Buy
Analyst Count
8
6
Target Price
$28.38
$16.50
AVG Volume (30 Days)
710.6K
2.1M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$719,887,000.00
N/A
Revenue This Year
$6.90
N/A
Revenue Next Year
$4.64
$16,320.74
P/E Ratio
$137.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.65
$1.85
52 Week High
$31.26
$7.18

Technical Indicators

Market Signals
Indicator
AMPH
ANNX
Relative Strength Index (RSI) 44.87 48.41
Support Level $16.84 $4.80
Resistance Level $20.08 $5.61
Average True Range (ATR) 0.80 0.28
MACD 0.11 0.02
Stochastic Oscillator 73.53 55.96

Price Performance

Historical Comparison
AMPH
ANNX

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: